COGT

Cogent Biosciences Inc

COGT, USA

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

https://www.cogentbio.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
COGT
stock
COGT

Cogent Biosciences Stock Surged by Positive Pivotal Trial Results StocksToTrade

Read more →
COGT
stock
COGT

Frazier Life Sciences Management L.P. Grows Stake in Cogent Biosciences, Inc. $COGT MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$47.1818

Analyst Picks

Strong Buy

5

Buy

4

Hold

3

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

15.94

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-26.76 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-19.00 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.41

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 97.30% of the total shares of Cogent Biosciences Inc

1.

FMR Inc

(12.225%)

since

2025/06/30

2.

Paradigm Biocapital Advisors LP

(7.4104%)

since

2025/06/30

3.

BlackRock Inc

(6.175%)

since

2025/06/30

4.

Kynam Capital Management, LP

(6.0791%)

since

2025/06/30

5.

TCG Crossover Management, LLC

(4.9852%)

since

2025/06/30

6.

Vanguard Group Inc

(4.6692%)

since

2025/06/30

7.

Fairmount Funds Management LLC

(4.4564%)

since

2025/06/30

8.

Point72 Asset Management, L.P.

(3.516%)

since

2025/06/30

9.

VR Adviser, LLC

(3.404%)

since

2025/06/30

10.

Vanguard Total Stock Mkt Idx Inv

(2.9093%)

since

2025/07/31

11.

UBS Group AG

(2.5187%)

since

2025/06/30

12.

Fidelity Select Health Care

(2.4195%)

since

2025/07/31

13.

State Street Corp

(2.4137%)

since

2025/06/30

14.

Vestal Point Capital LP

(2.2047%)

since

2025/06/30

15.

HHG PLC

(2.0566%)

since

2025/06/30

16.

Octagon Capital Advisors LP

(1.9778%)

since

2025/06/30

17.

Geode Capital Management, LLC

(1.9127%)

since

2025/06/30

18.

Deerfield Management Co

(1.8899%)

since

2025/06/30

19.

Fidelity Advisor Biotechnology I

(1.8459%)

since

2025/07/31

20.

Fidelity Small Cap Growth

(1.8419%)

since

2025/06/30

21.

iShares Russell 2000 ETF

(1.8404%)

since

2025/08/31

22.

Sofinnova Ventures

(1.6861%)

since

2025/06/30

23.

COMMODORE CAPITAL LP

(1.6544%)

since

2025/06/30

24.

Saturn V Capital Management LLC

(1.6446%)

since

2025/06/30

25.

Fidelity Advisor Health Care I

(1.36%)

since

2025/07/31

26.

FIAM Small Cap Core Composite

(1.3363%)

since

2025/03/31

27.

Nantahala Capital Management, LLC

(1.1852%)

since

2025/06/30

28.

Fidelity Select Biotechnology

(1.1214%)

since

2025/07/31

29.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9914%)

since

2025/07/31

30.

Fidelity Stock Selector Small Cap

(0.9168%)

since

2025/06/30

31.

Strategic Advisers Fidelity US TtlStk

(0.8447%)

since

2025/07/31

32.

Fidelity Small Cap Growth K6

(0.8282%)

since

2025/06/30

33.

Fidelity Series Small Cap Opps

(0.809%)

since

2025/06/30

34.

SPDR® S&P Biotech ETF

(0.7994%)

since

2025/08/31

35.

Fidelity Small Cap Index

(0.7629%)

since

2025/06/30

36.

iShares Russell 2000 Growth ETF

(0.6303%)

since

2025/08/31

37.

Belfius Equities Cure C Cap

(0.5528%)

since

2025/08/31

38.

Fidelity Extended Market Index

(0.5017%)

since

2025/07/31

39.

iShares Biotechnology ETF

(0.4806%)

since

2025/08/31

40.

Schwab US Small-Cap ETFâ„¢

(0.4413%)

since

2025/08/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

No earnings data available.

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(2.5)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.